Alpine Immune Sciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Alpine Immune Sciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||||||||||||||
| cash and cash equivalents | 33,015,000 | 43,921,000 | 18,981,000 | 34,076,000 | 14,465,000 | 13,376,000 | 126,625,000 | 24,360,000 | 34,889,000 | 67,907,000 | 76,099,000 | 18,813,000 | 12,629,000 | 34,959,000 | 141,075,000 | 88,220,000 | 24,446,000 | 16,123,000 | 17,395,000 | 15,468,000 | 41,437,000 | 10,711,000 | 11,473,000 | 3,569,000 | 7,446,000 | 8,000,000 | 11,982,000 | 27,548,000 | 12,929,000 | 16,168,000 | 15,416,000 | 16,030,000 | 24,991,000 | 57,555,000 | 100,521,000 | |
| short-term investments | 272,646,000 | 283,491,000 | 174,472,000 | 169,724,000 | 180,460,000 | 224,265,000 | 122,237,000 | 143,500,000 | 136,980,000 | 94,396,000 | 104,529,000 | 72,247,000 | 84,185,000 | 70,622,000 | 1,998,000 | 11,237,000 | 24,397,000 | 29,193,000 | 40,097,000 | 22,519,000 | 41,592,000 | 50,509,000 | 66,376,000 | 69,206,000 | 73,240,000 | 75,219,000 | ||||||||||
| accounts receivable | 42,000 | 167,000 | 219,000 | 284,000 | 668,000 | 392,000 | 382,000 | 1,317,000 | 132,000 | 25,000,000 | 45,343,000 | |||||||||||||||||||||||||
| prepaid expenses and other current assets | 2,548,000 | 2,455,000 | 3,743,000 | 3,237,000 | 3,191,000 | 2,960,000 | 3,995,000 | 3,112,000 | 4,095,000 | 4,710,000 | 3,121,000 | 3,333,000 | 3,668,000 | 1,520,000 | 1,475,000 | 1,018,000 | 2,273,000 | 1,650,000 | 5,734,000 | 1,657,000 | 939,000 | 1,242,000 | 1,098,000 | 1,850,000 | 1,335,000 | 1,308,000 | 884,000 | 129,000 | 263,000 | 843,000 | 480,000 | 501,000 | 432,000 | 996,000 | 569,000 | |
| total current assets | 308,251,000 | 330,034,000 | 197,415,000 | 207,321,000 | 198,784,000 | 240,993,000 | 253,239,000 | 172,289,000 | 176,096,000 | 192,013,000 | 183,749,000 | 139,736,000 | 100,482,000 | 107,101,000 | 142,550,000 | 91,236,000 | 38,088,000 | 42,302,000 | 52,454,000 | 57,222,000 | 64,895,000 | 53,545,000 | 63,080,000 | 71,795,000 | 77,987,000 | 82,548,000 | 88,085,000 | 49,626,000 | 52,937,000 | 67,030,000 | 74,214,000 | 80,713,000 | 87,686,000 | 93,647,000 | 101,090,000 | |
| restricted cash, noncurrent | 269,000 | 268,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | 254,000 | |||||||||||||||||
| property and equipment | 1,356,000 | 1,484,000 | 1,533,000 | 1,672,000 | 1,689,000 | 1,584,000 | 1,608,000 | 1,596,000 | 1,728,000 | 1,716,000 | 1,372,000 | 1,527,000 | 1,674,000 | 1,785,000 | 1,695,000 | 1,531,000 | 1,669,000 | 1,552,000 | 1,201,000 | 1,176,000 | 1,221,000 | 1,196,000 | 1,296,000 | 1,197,000 | 1,127,000 | 1,089,000 | 1,116,000 | |||||||||
| operating lease, right-of-use asset | 7,317,000 | 7,510,000 | 7,697,000 | 7,877,000 | 8,051,000 | 8,219,000 | 8,381,000 | 8,539,000 | 8,691,000 | 8,837,000 | 8,980,000 | 9,118,000 | 9,251,000 | 9,401,000 | 9,534,000 | 9,674,000 | 9,838,000 | 9,985,000 | 10,830,000 | 11,303,000 | 603,000 | |||||||||||||||
| long-term investments | 56,453,000 | 40,556,000 | 33,502,000 | 35,561,000 | 53,170,000 | 35,481,000 | 28,016,000 | 33,041,000 | 46,948,000 | 52,866,000 | 39,064,000 | 9,120,000 | 18,316,000 | 25,549,000 | ||||||||||||||||||||||
| total assets | 373,646,000 | 379,852,000 | 240,547,000 | 252,836,000 | 262,100,000 | 286,686,000 | 291,599,000 | 215,826,000 | 233,938,000 | 255,900,000 | 233,480,000 | 159,818,000 | 129,977,000 | 144,090,000 | 154,033,000 | 102,695,000 | 49,849,000 | 54,093,000 | 64,739,000 | 70,087,000 | 67,105,000 | 54,873,000 | 64,508,000 | 73,124,000 | 80,699,000 | 85,222,000 | 90,786,000 | 49,644,000 | 53,009,000 | 61,935,000 | 67,342,000 | 74,565,000 | 80,937,000 | 87,909,000 | 93,842,000 | 101,247,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||||||||||||||
| accounts payable | 4,170,000 | 3,593,000 | 3,068,000 | 1,645,000 | 1,662,000 | 4,286,000 | 3,240,000 | 1,812,000 | 1,903,000 | 3,349,000 | 1,839,000 | 1,393,000 | 466,000 | 582,000 | 742,000 | 548,000 | 468,000 | 1,543,000 | 5,778,000 | 2,399,000 | 743,000 | 1,716,000 | 440,000 | 750,000 | 528,000 | 193,000 | 1,076,000 | 815,000 | 1,278,000 | 1,012,000 | 2,110,000 | 1,196,000 | 994,000 | 1,552,000 | 3,432,000 | |
| accrued liabilities | 16,891,000 | 21,187,000 | 17,788,000 | 13,684,000 | 12,030,000 | 14,003,000 | 13,744,000 | 12,525,000 | 9,203,000 | 9,417,000 | 8,653,000 | 4,614,000 | 3,953,000 | 5,777,000 | 5,065,000 | 3,824,000 | 2,551,000 | 5,285,000 | 5,825,000 | 5,518,000 | 5,371,000 | 4,277,000 | 4,314,000 | 585,000 | 586,000 | 382,000 | 642,000 | |||||||||
| deferred revenue, current | 10,227,000 | 16,288,000 | 30,092,000 | 37,252,000 | 40,401,000 | 35,571,000 | 46,210,000 | 42,917,000 | 51,760,000 | 51,773,000 | 48,100,000 | 48,957,000 | 34,522,000 | 31,627,000 | 28,505,000 | 23,688,000 | ||||||||||||||||||||
| operating lease liability, current | 950,000 | 912,000 | 870,000 | 829,000 | 790,000 | 756,000 | 718,000 | 682,000 | 647,000 | 617,000 | 747,000 | 715,000 | 684,000 | 655,000 | 219,000 | 452,000 | ||||||||||||||||||||
| total current liabilities | 32,238,000 | 41,980,000 | 51,818,000 | 53,410,000 | 57,089,000 | 57,996,000 | 68,459,000 | 62,618,000 | 68,165,000 | 69,778,000 | 63,933,000 | 60,246,000 | 43,367,000 | 41,167,000 | 35,849,000 | 28,179,000 | 5,105,000 | 8,681,000 | 13,672,000 | 12,556,000 | 8,848,000 | 8,127,000 | 6,867,000 | 3,426,000 | 2,928,000 | 1,895,000 | 2,724,000 | 3,578,000 | 3,789,000 | 5,238,000 | 5,873,000 | 4,578,000 | 4,419,000 | 4,465,000 | 6,123,000 | |
| deferred revenue, noncurrent | 929,000 | 17,812,000 | 20,475,000 | 25,636,000 | 39,185,000 | 30,803,000 | 42,083,000 | 37,346,000 | 50,830,000 | 30,961,000 | 38,621,000 | 15,250,000 | 21,348,000 | 29,988,000 | 36,468,000 | |||||||||||||||||||||
| operating lease liability, noncurrent | 8,705,000 | 9,002,000 | 9,286,000 | 9,563,000 | 9,832,000 | 10,085,000 | 10,328,000 | 10,564,000 | 10,794,000 | 11,009,000 | 11,214,000 | 11,413,000 | 11,608,000 | 11,815,000 | 11,987,000 | 11,947,000 | 11,716,000 | 11,429,000 | 11,350,000 | 10,919,000 | ||||||||||||||||
| total liabilities | 40,943,000 | 51,911,000 | 78,916,000 | 83,448,000 | 92,557,000 | 107,266,000 | 109,590,000 | 116,290,000 | 118,511,000 | 134,997,000 | 110,655,000 | 115,987,000 | 76,683,000 | 81,932,000 | 86,565,000 | 86,467,000 | 24,990,000 | 24,619,000 | 29,908,000 | 24,666,000 | 10,522,000 | 10,282,000 | 9,524,000 | 6,577,000 | 6,818,000 | 6,305,000 | 7,814,000 | 6,499,000 | ||||||||
| commitments and contingencies | ||||||||||||||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at march 31, 2024 and december 31, 2023; zero shares issued and outstanding at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||||||||||
| common stock | 66,000 | 60,000 | 49,000 | 49,000 | 48,000 | 46,000 | 44,000 | 30,000 | 30,000 | 30,000 | 29,000 | 24,000 | 24,000 | 24,000 | 24,000 | 19,000 | 19,000 | 19,000 | 19,000 | 19,000 | 19,000 | 14,000 | 14,000 | 14,000 | 14,000 | 14,000 | 1,000 | 16,000 | 16,000 | 16,000 | 15,000 | 15,000 | 15,000 | 15,000 | 15,000 | |
| additional paid-in capital | 606,963,000 | 583,629,000 | 424,227,000 | 420,372,000 | 407,129,000 | 404,456,000 | 388,731,000 | 292,699,000 | 290,184,000 | 287,345,000 | 273,813,000 | 181,300,000 | 179,746,000 | 177,947,000 | 177,009,000 | 119,651,000 | 118,417,000 | 117,371,000 | 116,591,000 | 115,704,000 | 115,031,000 | 90,664,000 | 89,933,000 | 89,387,000 | 88,864,000 | 88,346,000 | 88,049,000 | 238,980,000 | 238,434,000 | 234,670,000 | 233,808,000 | 233,016,000 | 232,309,000 | 231,621,000 | 231,294,000 | |
| accumulated other comprehensive income | -263,000 | -14,000 | 5,000 | 23,000 | 3,000 | 3,000 | 15,000 | |||||||||||||||||||||||||||||
| accumulated deficit | -274,063,000 | -256,145,000 | -262,105,000 | -250,383,000 | -237,227,000 | -223,961,000 | -205,097,000 | -191,824,000 | -173,726,000 | -166,199,000 | -151,032,000 | -137,538,000 | -126,509,000 | -115,866,000 | -109,524,000 | -103,387,000 | -93,459,000 | -87,926,000 | -81,786,000 | -70,311,000 | -58,455,000 | -46,074,000 | -34,938,000 | -22,799,000 | -14,892,000 | -9,384,000 | -5,066,000 | -192,926,000 | -189,216,000 | -180,300,000 | -172,587,000 | -165,154,000 | -156,675,000 | -148,837,000 | -142,274,000 | -136,185,000 |
| total stockholders’ equity | 332,703,000 | 327,941,000 | 161,631,000 | 169,388,000 | 169,543,000 | 179,420,000 | 182,009,000 | 99,536,000 | 115,427,000 | 120,903,000 | 122,825,000 | 43,831,000 | 53,294,000 | 62,158,000 | 67,468,000 | 16,228,000 | 24,859,000 | 29,474,000 | 34,831,000 | 45,421,000 | 56,583,000 | 44,591,000 | 54,984,000 | 66,547,000 | 73,881,000 | 82,972,000 | 46,066,000 | 49,220,000 | 62,104,000 | 68,692,000 | 76,359,000 | 83,490,000 | 89,377,000 | 95,124,000 | ||
| total liabilities and stockholders’ equity | 373,646,000 | 379,852,000 | 240,547,000 | 252,836,000 | 262,100,000 | 286,686,000 | 291,599,000 | 215,826,000 | 233,938,000 | 255,900,000 | 233,480,000 | 159,818,000 | 129,977,000 | 144,090,000 | 154,033,000 | 102,695,000 | 49,849,000 | 54,093,000 | 64,739,000 | 70,087,000 | 67,105,000 | 49,644,000 | 53,009,000 | 67,342,000 | 74,565,000 | 80,937,000 | 87,909,000 | 93,842,000 | 101,247,000 | |||||||
| deferred tax asset | 146,000 | 151,000 | 152,000 | 155,000 | 101,000 | 107,000 | 221,000 | 214,000 | 61,000 | 63,000 | ||||||||||||||||||||||||||
| current portion of long-term debt | 2,206,000 | 3,380,000 | 4,547,000 | 4,682,000 | 4,652,000 | 4,622,000 | 4,594,000 | 4,567,000 | 3,742,000 | 2,526,000 | 1,318,000 | 119,000 | 1,742,000 | 418,000 | 2,079,000 | 2,064,000 | 2,048,000 | 2,034,000 | 2,018,000 | 1,508,000 | 995,000 | 490,000 | ||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2023 and 2022; zero shares issued and outstanding at december 31, 2023 and 2022 | ||||||||||||||||||||||||||||||||||||
| treasury stock | ||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive gain | 397,000 | -273,000 | 15,000 | 45,000 | 33,000 | 53,000 | -41,000 | -55,000 | -118,000 | 10,000 | 7,000 | 9,000 | ||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at september 30, 2023 and december 31, 2022; zero shares issued and outstanding at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -540,000 | -650,000 | -407,000 | -1,121,000 | -1,669,000 | -1,369,000 | -1,061,000 | -12,000 | -13,000 | -25,000 | -55,000 | -105,000 | -59,000 | -12,000 | ||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at june 30, 2023 and december 31, 2022; zero shares issued and outstanding at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at march 31, 2023 and december 31, 2022; zero shares issued and outstanding at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||||||||||
| long-term debt | 1,025,000 | 2,206,000 | 3,380,000 | 4,547,000 | 5,707,000 | 6,458,000 | 7,602,000 | 8,741,000 | 9,873,000 | 8,169,000 | 4,509,000 | 4,886,000 | 1,191,000 | 1,674,000 | 2,155,000 | 2,631,000 | 3,104,000 | 3,570,000 | 4,039,000 | 4,500,000 | ||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2022 and 2021; zero shares issued and outstanding at december 31, 2022 and 2021 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at september 30, 2022 and december 31, 2021; zero shares issued and outstanding at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at june 30, 2022 and december 31, 2021; zero shares issued and outstanding at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at march 31, 2022 and december 31, 2021; zero shares issued and outstanding at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2021 and 2020; zero shares issued and outstanding at december 31, 2021 and 2020 | ||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at september 30, 2021 and december 31, 2020; zero shares issued and outstanding at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at june 30, 2021 and december 31, 2020; zero shares issued and outstanding at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||||||||||
| restricted cash, current | 132,000 | 132,000 | 132,000 | |||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2020 and 2019; zero shares issued and outstanding at december 31, 2020 and 2019 | ||||||||||||||||||||||||||||||||||||
| deferred revenue | 344,000 | 1,435,000 | 2,069,000 | 2,108,000 | 240,000 | 277,000 | 405,000 | |||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2019 and 2018; zero shares issued and outstanding at december 31, 2019 and 2018 | ||||||||||||||||||||||||||||||||||||
| restricted cash | 386,000 | 386,000 | 132,000 | 132,000 | 132,000 | 132,000 | 132,000 | 132,000 | ||||||||||||||||||||||||||||
| deferred rent, current portion | 86,000 | 79,000 | 73,000 | 66,000 | 48,000 | 44,000 | ||||||||||||||||||||||||||||||
| operating lease liability | 670,000 | |||||||||||||||||||||||||||||||||||
| intangible assets | 1,453,000 | 1,453,000 | 1,453,000 | |||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||||||||||||||||||||||
| deferred rent, long-term portion | 26,000 | 47,000 | 67,000 | 66,000 | 81,000 | |||||||||||||||||||||||||||||||
| deferred tax liability | 253,000 | 305,000 | 509,000 | |||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at december 31, 2018 and 2017; zero shares issued and outstanding at december 31, 2018 and 2017 | ||||||||||||||||||||||||||||||||||||
| total liabilities, convertible preferred stock, and stockholders’ equity | 54,873,000 | 64,508,000 | 73,124,000 | 80,699,000 | 90,786,000 | |||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at september 30, 2018 and december 31, 2017; zero shares issued and outstanding at september 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at june 30, 2018 and december 31, 2017; zero shares issued and outstanding at june 30, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value per share; 10,000,000 shares authorized at march 31, 2018 and december 31, 2017; zero shares issued and outstanding at march 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders' equity | ||||||||||||||||||||||||||||||||||||
| income taxes payable | 67,000 | |||||||||||||||||||||||||||||||||||
| convertible preferred stock, 0.001 par value, 10,000,000 shares authorized and zero shares issued and outstanding at december 31, 2017; 0.0001 par value, 22,081,852 shares authorized and 4,311,770 shares issued and outstanding at december 31, 2016; aggregate liquidation preference of zero and 11,583 at december 31, 2017 and 2016, respectively | ||||||||||||||||||||||||||||||||||||
| stockholders' equity | ||||||||||||||||||||||||||||||||||||
| total stockholders' equity | 78,917,000 | 55,436,000 | ||||||||||||||||||||||||||||||||||
| total liabilities, redeemable convertible preferred stock and stockholders' equity | 85,222,000 | |||||||||||||||||||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders’ deficit | ||||||||||||||||||||||||||||||||||||
| convertible preferred stock | ||||||||||||||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||||||||||||||
| marketable securities | 21,949,000 | 39,745,000 | 50,019,000 | 58,318,000 | 64,182,000 | 62,263,000 | 35,096,000 | |||||||||||||||||||||||||||||
| property and equipment and other assets | 18,000 | 72,000 | 312,000 | 351,000 | 224,000 | 223,000 | 195,000 | 157,000 | ||||||||||||||||||||||||||||
| accrued direct program expenses | 8,000 | 87,000 | 2,837,000 | 2,742,000 | 2,609,000 | 1,555,000 | 1,457,000 | 1,682,000 | ||||||||||||||||||||||||||||
| accrued restructuring charges | 2,584,000 | 2,251,000 | ||||||||||||||||||||||||||||||||||
| accrued employee benefits | 146,000 | 119,000 | 1,345,000 | 985,000 | 712,000 | 1,675,000 | 1,336,000 | 977,000 | ||||||||||||||||||||||||||||
| accrued other liabilities | 25,000 | 54,000 | 44,000 | 36,000 | 61,000 | 195,000 | 120,000 | 32,000 | ||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized and no shares issued and outstanding for both periods presented | ||||||||||||||||||||||||||||||||||||
| cash, cash equivalents and marketable securities | 61,035,000 | |||||||||||||||||||||||||||||||||||
| working capital | 55,164,000 | |||||||||||||||||||||||||||||||||||
| convertible preferred stock with liquidation preference; 0.001 par value; zero and 23,228,986 shares authorized, respectively; zero and 19,978,986 shares issued and outstanding, respectively | ||||||||||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 and zero shares authorized, respectively; no shares issued and outstanding |
We provide you with 20 years of balance sheets for Alpine Immune Sciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Alpine Immune Sciences. Explore the full financial landscape of Alpine Immune Sciences stock with our expertly curated balance sheets.
The information provided in this report about Alpine Immune Sciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.